Groundbreaking Drug Launches
Remibrutinib (Rhapsido)
Mechanism of Action: Agammaglobulinaemia tyrosine kinase inhibitors Drug class: Small molecules Originator: Novartis Indication: Chronic urticaria
Launched Date: October 2025 Trials: REMIX-1 and REMIX-2
Chronic urticaria
Chronic hives, also known as chronic urticaria, are persistent red, itchy welts on the skin that last for more than six weeks and may continue daily for months or even years. Individuals with autoimmune conditions are at higher risk, though in many cases the underlying cause remains unknown. Treatments such as antihistamines, steroids, and immunosuppressive therapies are commonly used to help control symptoms.
Impact and Management:
- Debilitating Effects: Chronic hives can be highly disruptive, leading to significant discomfort, fatigue, sleep disturbances, anxiety, and depression.
- Treatment Approach: Antihistamines are typically the first line of therapy, while more severe or persistent cases may require specialist care and advanced treatments such as steroids or other immunosuppressive medications.
- Outlook: Around half of patients experience spontaneous remission within five years, though many require ongoing, long-term management.
Treatment challenges Managing chronic urticaria (hives) is challenging due to difficulty identifying unknown triggers, variable response to standard antihistamines—which may require higher doses or advanced therapies like omalizumab—and coexisting conditions such as autoimmune disorders. Additional hurdles include addressing emotional and lifestyle factors like stress and fatigue, navigating treatment costs and insurance coverage, and ensuring equitable access to newer therapies, particularly for patients with skin of color.
Why is Remibrutinib poised to make an impact in 2026?
Remibrutinib (Rhapsido) is a highly selective, covalent, oral small-molecule Bruton's tyrosine kinase (BTK) inhibitor developed by Novartis for the treatment of chronic spontaneous urticaria, chronic inducible urticaria, multiple sclerosis, peanut hypersensitivity, myasthenia gravis, and hidradenitis suppurativa. Rhapsido is expected to be a major therapy to watch in 2026, driven by its launch and early adoption as the first oral Bruton's tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria (CSU).
Key factors behind its anticipated impact include:
- First-in-Class Oral Therapy for CSU: Developed by Novartis, Rhapsido was approved in September 2025 for adults with CSU who remain symptomatic despite H1-antihistamines. It introduces a convenient oral alternative to injectable biologics, meeting a clear patient preference and unmet need.
- Compelling Commercial Outlook: Analysts have expressed strong confidence in the launch, with expectations that uptake in CSU could exceed consensus forecasts and support substantial long-term sales potential across indications.
- Innovative Mechanism of Action: As a selective BTK inhibitor, Rhapsido targets a central immune signaling pathway, limiting histamine and inflammatory mediator release from mast cells and basophils and enabling rapid symptom control.
- Broader Development Potential: Beyond CSU, Rhapsido is being evaluated in several inflammatory conditions, including multiple sclerosis, chronic inducible urticaria, and food allergy, positioning it for an expanding role in immune-mediated diseases in the years ahead.
Novartis’s Rhapsido is forecast to generate around $500 million in annual revenue by 2026, with analysts highlighting strong upside potential as the drug expands across indications.
- Peak Sales Opportunity: Rhapsido is viewed as having peak sales potential exceeding $5 billion across multiple indications, including chronic inducible urticaria and multiple sclerosis, with key clinical readouts anticipated in 2026.
- Long-Term Prospects: Some analysts suggest revenues could reach $1 billion annually by 2028, depending on successful regulatory approvals, competitive positioning, and effective pricing strategies.
“Rhapsido is seen as a high-growth asset with multibillion-dollar peak sales potential across several indications, supported by key clinical milestones and strong long-term revenue prospects.”
Regulatory milestones for Remibrutinib
Registrational Trials
The U.S. FDA has approved remibrutinib (Rhapsido®) as an oral therapy for adults with chronic spontaneous urticaria who continue to experience symptoms despite H1 antihistamine treatment, based on results from the REMIX-1 and REMIX-2 clinical trials.
REMIX-1:
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines (NCT05030311).
“The REMIX-1 trial showed that remibrutinib significantly reduced disease activity and improved symptom control in patients with chronic spontaneous urticaria compared with placebo.”
“The REMIX-2 trial confirmed remibrutinib’s efficacy, demonstrating meaningful symptom improvement in patients with chronic spontaneous urticaria versus placebo.”
REMIX-2:
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines (NCT05032157).
